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Dear Editor,
Bone marrow chimerism (BMC) develops after allogeneic he-
matopoietic stem cell transplantion (HSCT); however, BMC is 
also associated with graft-versus-host disease (GVHD) following 
liver transplantation, which has an incidence rate of 0.1-2% and 
a mortality rate exceeding 75% [1]. Therefore, detecting BMC is 
also important in solid organ transplantation (SOT) as well as 
HSCT, and accurate quantification is needed, especially in case 
of clonality distinction of minimal portions. This study aimed to 
introduce the significance of BMC in SOT, by using conventional 
short tandem repeat (STR)-PCR [2-4] and next generation se-
quencing (NGS), through relative quantification of single-nucle-
otide polymorphisms (SNP).
A 55-yr-old Korean woman underwent liver transplantation 
owing to decompensated hepatitis C virus-related cirrhosis. The 
donor was a 40-yr-old woman who died from subarachnoid 
hemorrhage due to Moyamoya disease. After the operation, the 
patient received immunosuppressive therapy consisting of pred-
nisone, one injection of basiliximab, and low-dose tacrolimus, 
which was discontinued when GVHD symptoms appeared. The 
patient developed fever of 39°C 23 days after the transplant, 
with five days of severe leucopenia (0.38×109 white blood cells 
[WBC]/L), accompanied by anemia (6.4g of Hb/dL) and throm-
bocytopenia (81×109 platelets/L) with symptoms suggesting 
GVHD. Pancytopenia persisted despite administration of granu-
locyte-colony-stimulating factor. Bone marrow was aspirated to 
evaluate the etiology of hematologic disorder and to diagnose 
GVHD. Hypocellular marrow was observed, and BMC was ana-
lyzed simultaneously. The therapy was initiated to control GVHD, 
including substitution of tacrolimus with cyclosporin A and in-
creasing mycophenolate mofetil. However, despite transfusion 
support, broad-spectrum antibiotics, and antifungal therapy, the 
patient died of sepsis due to Klebsiella pneumoniae infection.
BMC was analyzed with stored, pre-transplant WBC pellets 
from both recipient and donor. DNA was extracted from the pel-
lets with QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Ger-
many). Chimerism was analyzed by STR-PCR using the Ge-
nomeLab Human STR Primer Set (Beckman Coulter, Fullerton, 
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CA, USA), in which 11 polymorphic STR alleles were amplified 
and labeled with different fluorescent dyes. The PCR products 
were separated in a CEQ 8800 Capillary Electrophoresis System 
(Beckman Coulter). The percent chimerism was estimated as 
the average of percent recipient peaks observed for each distin-
guishable marker [5] (Table 1).
BMC was also analyzed with NGS by using the HID-Ion Am-
liSeq Identity Panel (Life Technologies, Milan, Italy). Bar-coded 
libraries were generated by using the Ion Xpress Plus Fragment 
Library Kit (Life Technologies) and Ion Xpress DNA Bar Coding 
Kit (Life Technologies) with adaptors. The panel selectively ana-
lyzed gene content by discriminating 120 SNPs, including 90 
autosomal SNPs and 30 upper Y-Clade SNPs. Since both the 
donor and recipient were women, 30 upper Y-Clade SNPs were 
not used. Out of 90 SNPs, 32 sequence variations were ob-
served and read number of variant sequence per read number 
of expected sequence was calculated to determine percent chi-
merism (Fig. 1).
The percentage of recipient DNA determined in mixed chime-
Table 1. Recipient pre-transplant and donor STR alleles
STR markers Recipient Donor
Amelogenin X,X X,X
D3S1358* 16,16 15,15
TH01* 6,9.3 7,9
D13S317* 9,12 8,12
D8S1179 13,13 13,15
D7S820* 11,11 8,10
TPOX 8,11 8,12
D16S539* 9,11 12,13
D18S51* 13,18 15,16
CSF1PO 12,12 11,12
Penta D* 11,13 9,9
Penta E 15,16 12,18
Eight of eleven markers discriminated between the donor and recipient in 
STR-PCR chimerism analysis 41 days after liver transplant (when pancyto-
penia persisted). D3S1358, TH01, D13S317, D7S820, D16S539, D18S51, 
Penta D, and Penta E markers were used for the chimerism calculation.
*Recipient-specific alleles used in the chimerism calculation.
Abbreviation: STR, short tandem repeat.
Fig. 1. NGS chimerism analysis 41 days after liver transplant. Thirty-two of ninety SNPs discriminated between the donor and recipient. 
The average percent of donor DNA was 95.1%. Ninety SNPs are shown for (A) the recipient (peripheral blood, pre-transplant), (B) donor 
(peripheral blood), and (C) recipient (bone marrow, post-transplant) with mean coverage depth for each SNPs, 674, 1,609 and 1,080, re-
spectively. The following markers were used for the chimerism calculation: rs560681, rs891700, rs12997453, rs6444724, rs2046361, 
rs159606, rs251934, rs338882, rs13218440, rs727811, rs10092491, rs2056277, rs1463729, rs735155, rs740598, rs964681, 
rs2076848, rs2269355, rs2111980, rs1058083, rs354439, rs873196, rs2016276, rs1382387, rs9905977, rs2292972, rs1736442, 
rs719366, rs1005533, rs722098, rs2830795, and rs987640.
*discriminating SNPs used in chimerism calculation.
Abbreviations: NGS, next generation sequencing; SNPs, single nucleotide polymorphisms.
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rism analyses were 5.6% (range 4.1-7.7%) by STR-PCR and 
4.9% (range 2.5-6.7%) by NGS. The percent recipient DNA de-
termined by NGS was equivalent to that determined by STR-
PCR, indicating its applicability in chimerism analysis.
Pancytopenia after SOT is the presenting symptom of life-
threatening pathologies, such as SOT-GVHD, post-transplant 
lymphoproliferative disorder, or unsuspected opportunistic in-
fection [6]. Although lymphocyte macrochimerism can occur 
transiently and decrease rapidly over time, usually within the 
third postoperative week [7], this study illustrates an occurrence 
of BMC six weeks after liver transplantation, with 95.1% of the 
DNA originating from the donor. This high donor chimerism has 
been associated with liver transplants from deceased donors 
and recipients with hepatitis C virus [3]. The relative amount of 
DNA from the recipient was 4.9%, which was too low to be reli-
ably distinguished from background noise and could cause 
misinterpretation in cases of mixed chimerism [8]. Here, we 
used NGS to quantify chimerism and confirmed the applicability 
of this method by comparing with conventional STR-PCR. NGS 
is an emerging, promising diagnostic tool for a number of clini-
cal applications and forensic analyses [9]. The present observa-
tions may have implications in the field of transplantation re-
search and exhibit the diagnostic utility of this new technology.
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